CD8A and melanoma: Researchers synthesized protein nanogels (NGs) carrying proteins such as a new IL-15 superagonist (IL-15-Sa—a fusion molecule between a mutant of IL-15, 15N72D, that has increased binding capabilities, and the IL-RaSu domain with the human IgG1 Fc domain),104 anti-CD45 or IL-2Fc (a fusion protein contain IL-2 fused with an antibody Fc fragment) and coupled them to T cells to target CD2, CD8, CD11α, and CD90 expressing melanoma cells in vitro and in vivo.